PAVS Stock Overview
Paranovus Entertainment Technology Ltd. engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People’s Republic of China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Paranovus Entertainment Technology Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.14 |
| 52 Week High | US$5.03 |
| 52 Week Low | US$0.99 |
| Beta | 0.054 |
| 1 Month Change | -39.04% |
| 3 Month Change | -57.62% |
| 1 Year Change | -76.35% |
| 3 Year Change | -96.71% |
| 5 Year Change | n/a |
| Change since IPO | -98.73% |
Recent News & Updates
Take Care Before Jumping Onto Paranovus Entertainment Technology Ltd. (NASDAQ:PAVS) Even Though It's 26% Cheaper
Mar 20
Sentiment Still Eluding Paranovus Entertainment Technology Ltd. (NASDAQ:PAVS)
Dec 20Recent updates
Take Care Before Jumping Onto Paranovus Entertainment Technology Ltd. (NASDAQ:PAVS) Even Though It's 26% Cheaper
Mar 20Sentiment Still Eluding Paranovus Entertainment Technology Ltd. (NASDAQ:PAVS)
Dec 20Happiness Development Group announces 1-for-20 reverse stock split
Oct 10Happiness Biotech Group (NASDAQ:HAPP) Could Be Struggling To Allocate Capital
Aug 05Happiness Biotech inks EV distribution agreement with Geely's subsidiary
Jun 10A Look At Happiness Biotech Group's (NASDAQ:HAPP) Share Price Returns
Mar 18Here's What To Make Of Happiness Biotech Group's (NASDAQ:HAPP) Returns On Capital
Jan 24
Happiness Biotech stock surge as its e-commerce business grew over 70% M/M in December
Jan 11Happiness Biotech rallies on subsidiary receiving policy granting 80% tax rebates from local government
Dec 16Would Shareholders Who Purchased Happiness Biotech Group's (NASDAQ:HAPP) Stock Year Be Happy With The Share price Today?
Nov 24Shareholder Returns
| PAVS | US Personal Products | US Market | |
|---|---|---|---|
| 7D | -18.6% | -2.9% | -3.7% |
| 1Y | -76.3% | -35.2% | 20.5% |
Return vs Industry: PAVS underperformed the US Personal Products industry which returned -35.3% over the past year.
Return vs Market: PAVS underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| PAVS volatility | |
|---|---|
| PAVS Average Weekly Movement | 12.0% |
| Personal Products Industry Average Movement | 8.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PAVS's share price has been volatile over the past 3 months.
Volatility Over Time: PAVS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 80 | Xuezhu Wang | www.pavs.ai |
Paranovus Entertainment Technology Ltd. engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People’s Republic of China and internationally. The company’s product category includes lucidum spore powders, cordyceps mycelia, Ejiao products, American ginseng products, other traditional Chinese herbal and animal extracts, vitamins, minerals, and amino acids. It also offers product marketing and e-commerce agency operation services under the Happy Buy platform to small and middle size businesses; and e-commerce solutions, internet information, and advertising services to the online stores or manufactures.
Paranovus Entertainment Technology Ltd. Fundamentals Summary
| PAVS fundamental statistics | |
|---|---|
| Market cap | US$7.92m |
| Earnings (TTM) | -US$59.86m |
| Revenue (TTM) | US$87.57m |
0.1x
P/S Ratio-0.1x
P/E RatioIs PAVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PAVS income statement (TTM) | |
|---|---|
| Revenue | US$87.57m |
| Cost of Revenue | US$82.90m |
| Gross Profit | US$4.67m |
| Other Expenses | US$64.53m |
| Earnings | -US$59.86m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.16 |
| Gross Margin | 5.33% |
| Net Profit Margin | -68.36% |
| Debt/Equity Ratio | 0% |
How did PAVS perform over the long term?
See historical performance and comparison